Home » PHmr
Tag:

PHmr

Health

Evaluating Optimal Timing for Hepatitis B Vaccination: Insights from Kennedy’s Vaccine Advisers

by Dr. Priya Deshmukh - Senior Editor, Health
written by Dr. Priya Deshmukh - Senior Editor, Health

Kennedy Administration Weighs Major Shift in Hepatitis B Vaccination Policy

Table of Contents

Washington D.C. – December 4, 2025 – In a move poised to dramatically reshape U.S. vaccination policy, advisors to Health Secretary Robert F.kennedy Jr. are deliberating whether to significantly alter the long-standing proposal for global hepatitis B vaccination for children. A vote is scheduled for later today, with the panel considering a proposal to limit the vaccine to infants born to mothers who test positive for hepatitis B, leaving the decision for all other newborns to parents in consultation with their healthcare providers.

The proposed change marks the most ample potential shift under Kennedy, a former anti-vaccine activist who has already implemented sweeping changes including relaxed COVID-19 vaccine recommendations, a split of the MMR vaccine for young children, and cuts to mRNA vaccine funding.

Currently, the U.S. recommends a three-dose hepatitis B vaccine series, beginning within 24 hours of birth, often administered in combination with other vital childhood immunizations.The proposed policy would delay the frist dose to at least two months of age for those who choose to vaccinate. Furthermore, the panel will vote on whether to require antibody testing before subsequent doses, assessing if a child has already developed protective immunity.

The proposal has drawn sharp criticism from numerous experts. Demetre Daskalakis, former director at the CDC’s National Center for Immunization and Respiratory Diseases, emphasized the importance of the three-dose regimen for lasting immunity, stating on X that single doses provide only temporary antibody levels. The World Health Institution continues to recommend universal vaccination shortly after birth.

A 1991 policy of universal hepatitis B vaccination has been credited with reducing infections in children by over 95%, according to a recent review of over 400 studies.

What evidence supports the claim that the timing of the Hepatitis B birth dose is crucial in regions with high prevalence, and how dose this compare to regions with robust prenatal screening?

Evaluating Optimal Timing for Hepatitis B Vaccination: Insights from Kennedy’s Vaccine Advisers

Understanding the Hepatitis B Vaccine Schedule

The Hepatitis B vaccine is a cornerstone of preventative healthcare, protecting against a possibly life-threatening liver infection. current recommendations, largely shaped by advisory groups and ongoing research, dictate a multi-dose schedule. However, recent scrutiny, notably stemming from discussions involving Robert F. kennedy Jr.’s vaccine advocacy and the insights of his assembled advisors, has prompted a re-evaluation of optimal timing for vaccine administration. This article delves into those considerations, focusing on the nuances of the standard schedule and potential adjustments. We’ll explore the science behind the timing, address concerns raised, and offer a extensive overview for informed decision-making regarding Hep B vaccination.

The standard Hepatitis B Vaccination Schedule: A Breakdown

the Centers for Disease Control and prevention (CDC) currently recommends the following schedule:

* Birth Dose: the first dose is typically administered within 24 hours of birth. This early dose is crucial for preventing mother-to-child transmission, especially in regions with high Hepatitis B prevalence.

* Subsequent Doses: The remaining doses are administered as a 2 or 3-dose series, depending on the vaccine product used. A common schedule involves doses at 1-2 months and 6 months of age.

* Catch-Up Vaccination: For individuals who missed the initial series, a 3-dose schedule is generally recommended.

This schedule aims to establish protective immunity as quickly as possible, leveraging the infant’s developing immune system.Hepatitis B immunization is vital for long-term health.

Concerns Raised by Kennedy’s Vaccine Advisers & Option Perspectives

Kennedy’s advisors have questioned the necessity and timing of the birth dose, citing concerns about potential immune overload in newborns and the limited window of maternal transmission risk in developed countries with robust screening programs. Their arguments center around:

* Neonatal Immune System Maturity: Newborns have an immature immune system.Introducing multiple antigens together, they argue, could potentially overwhelm the system.

* Maternal Transmission Rates: In countries with comprehensive prenatal screening for Hepatitis B, the risk of mother-to-child transmission is significantly reduced, leading some to question the universal need for the birth dose.

* Delayed Vaccination Strategies: Proponents of delayed vaccination suggest a schedule starting at 6 months, aligning with other routine childhood immunizations, potentially reducing the number of injections and simplifying the vaccination process. This approach is often framed as Hep B vaccine timing optimization.

It’s vital to note that these perspectives are frequently enough met with counterarguments from mainstream medical and public health organizations.

Scientific evidence Supporting the Current Schedule

Despite the concerns, substantial scientific evidence supports the current Hepatitis B vaccination schedule:

* Early Protection: The birth dose provides crucial protection against perinatal transmission, a notable risk factor in many parts of the world. Even in countries with low prevalence, sporadic cases of maternal transmission can occur.

* Immunogenicity in Newborns: Studies demonstrate that newborns are capable of mounting an immune response to the Hepatitis B vaccine,even with their immature immune systems.

* Safety Data: Extensive safety data from decades of use demonstrate the Hepatitis B vaccine is remarkably safe, with serious adverse events being exceedingly rare. Hepatitis B vaccine safety is continuously monitored.

* Long-Term Immunity: The current schedule consistently induces protective antibody levels in the vast majority of vaccinated individuals.

The Role of Antibody Titers and booster Doses

Monitoring antibody titers (levels of antibodies in the blood) after vaccination is becoming increasingly common. While the CDC doesn’t routinely recommend titer testing after the primary series, it can be considered in specific situations, such as:

* Immunocompromised Individuals: Those with weakened immune systems may not respond adequately to the vaccine and may require booster doses.

* Healthcare Workers: Regular monitoring of antibody titers is often recommended for healthcare professionals at risk of exposure.

* non-Responders: Individuals who initially fail to develop protective antibody levels.

Hepatitis B antibody testing can help determine the need for booster shots, ensuring continued protection.

Real-world Examples & Case studies

Several countries have experimented with alternative Hepatitis B vaccination schedules. Such as, some European nations initially delayed the first dose to 6 weeks or 2 months. However, these approaches often resulted in lower vaccination coverage rates and increased incidence of Hepatitis B among young adults. These experiences highlight the importance of adhering to evidence-based schedules.

A case study from a region with high Hepatitis B prevalence demonstrated a significant reduction in childhood liver cancer rates following the implementation of universal newborn vaccination. This underscores the public health benefits of early and widespread immunization.

Benefits of Timely hepatitis B Vaccination

* Prevention of Chronic Infection: The primary benefit is preventing chronic Hepatitis B infection, which can lead to cirrhosis, liver failure, and liver cancer.

* Reduced Liver Disease Burden: Widespread vaccination significantly reduces the overall burden of liver disease in the population.

* Protection of Family Members: Vaccination protects not only the individual but also their family members and community.

0 comments
0 FacebookTwitterPinterestEmail
world

US, UK drug tariffs reduced to zero on condition of increased NHS spending and new drug price hikes | Reuters

by Omar El Sayed - World Editor
written by Omar El Sayed - World Editor

US and UK Forge New Pharma Trade Pact: Tariffs Vanish, But UK Patients May Pay More

WASHINGTON/LONDON – In a move poised to reshape the transatlantic pharmaceutical landscape, the United States and the United Kingdom have announced a landmark agreement eliminating tariffs on pharmaceuticals and medical technology. However, the deal comes with significant concessions from the UK, including a commitment to increase the price it pays for new medicines and a shift in how it assesses their value. This is breaking news with potential ramifications for healthcare access and innovation on both sides of the Atlantic, and a story Archyde is following closely.

The Core of the Agreement: Zero Tariffs, Increased Costs

Effective immediately, British-made medicines, pharmaceutical ingredients, and medical technology will be exempt from Section 232 tariffs imposed by the US. In return, the UK has agreed to a 25% increase in the net purchase price of new medicines. Furthermore, the UK has pledged to lower its refund rate for medicines to 15% by the end of 2026. U.S. Trade Representative Greer hailed the agreement as a catalyst for “investment and innovation” in both countries.

This isn’t simply a trade adjustment; it’s a fundamental shift in the economic equation. For years, the US has argued that other developed nations benefit from lower drug prices at the expense of American pharmaceutical companies. President Trump has been particularly vocal in pushing for fairer pricing, and this deal appears to be a direct response to that pressure. Understanding the dynamics of international pharmaceutical trade is crucial to grasping the significance of this agreement.

NICE Changes: A New Era for UK Drug Evaluation

Perhaps the most impactful element of the agreement lies in the revisions to the National Institute for Health and Care Excellence (NICE) – the body responsible for determining the cost-effectiveness of new medicines for the NHS. NICE traditionally uses a quality-adjusted life year (QALY) measure, capped at £30,000 ($39,789) per year of health gained. This cap will now be raised to £35,000.

Sources familiar with the negotiations indicate that these changes represent a substantial overhaul of NICE’s value assessment framework. The UK government defends the move, stating it will “bring it in line with the commercial and economic environment” faced by pharmaceutical companies. While the changes apply to all new drugs, existing drug prices remain unaffected. This is a critical point: the immediate impact will be felt by future patients accessing innovative treatments.

Industry Reaction: Optimism Tempered with Caution

The British pharmaceutical industry, represented by the ABPI, has largely welcomed the agreement, predicting improved access to new medicines and increased investment. The British Chambers of Commerce echoed this sentiment, noting that pharmaceuticals constitute a significant portion of UK exports to the US – roughly a fifth by value. This deal provides a “clear advantage” for British companies.

However, concerns remain about the potential impact on the NHS budget and patient access. Critics argue that increasing the cost of new medicines could lead to rationing or delays in treatment. The long-term effects of these changes will require careful monitoring. For a deeper dive into the complexities of NICE’s role in healthcare, their official website provides comprehensive information.

AstraZeneca logo, photographed July 21, 2025. (Reuters/Umit Bektas)

Beyond the Headlines: The Future of Pharma Trade

This US-UK agreement could serve as a template for future trade negotiations with other European countries. The pressure on nations to increase drug prices is unlikely to subside, particularly as the US seeks to address its own high healthcare costs. The success of this deal will hinge on whether it truly fosters innovation without compromising access to essential medicines. For readers interested in staying ahead of the curve on pharmaceutical health news, Archyde will continue to provide in-depth coverage and analysis.

The implications of this agreement extend far beyond trade statistics. It’s a story about the delicate balance between innovation, affordability, and access to healthcare – a balance that will continue to be debated and redefined in the years to come. Stay tuned to Archyde for ongoing updates and expert insights on this evolving situation.

0 comments
0 FacebookTwitterPinterestEmail
Health

European Doctors Advocate Novo Nordisk and Eli Lilly Weight-Loss Drugs as Primary Obesity Treatment Options

by Dr. Priya Deshmukh - Senior Editor, Health
written by Dr. Priya Deshmukh - Senior Editor, Health
  • Most effective drugs for obesity and its complications are semaglutide, tirzepatide, new European guideline says
  • Certain GLP-1 drugs are best for specific complications
  • The non-binding guideline emphasizes economic considerations in obesity treatment
Oct 2 (Reuters) – Novo Nordisk’s (NOVOb.CO)opens new tab and Eli Lilly’s (LLY.N)opens new tab blockbuster weight-loss drugs should be the first medicines doctors reach for to treat obesity and its complications, a major European medical association advised on Thursday.

Semaglutide, the active ingredient in Novo’s Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European Association for the Study of Obesity published in Nature Medicine.

Sign up here.

When a lesser degree of weight loss is required, other medications can be considered, including liraglutide, an older, less effective drug from the same class, naltrexone–bupropion, and phentermine-topiramate, the guideline says.

Novo shares were up 2.2% at 1007 GMT, outperforming European pharmaceuticals peers.

The EASO guidelines are non-binding on individual countries.

Semaglutide, tirzepatide, and other drugs from the class known as GLP-1 agonists are completely transforming care of obesity and its complications, coauthor Dr. Andreea Ciudin of Vall d’Hebron University Hospital in Barcelona said in a statement.

Although no treatment algorithm can replace the nuanced clinical judgment necessary for comprehensive patient care, the new guidelines can serve to support therapeutic decision-making in obesity, she said.

SPECIFIC DRUGS FOR SPECIFIC CONDITIONS

Table of Contents

The guideline authors analyzed previous clinical trial results, evaluating the impact of medications on weight loss, their safety profile, and their effectiveness in the presence of specific complications.

For patients with the physical consequences of too much fatty, or adipose, tissue, tirzepatide should be considered as the first-line treatment for addressing obstructive sleep apnea, and semaglutide for those with knee osteoarthritis, the authors determined.

For patients with conditions linked with obesity-related metabolic and immune dysfunction, they recommend semaglutide as a first choice for those with a history of heart disease or stroke, tirzepatide for individuals with non-alcoholic fatty liver disease, and either tirzepatide or semaglutide for those with prediabetes or type 2 diabetes.

The class of drugs was originally developed to treat type 2 diabetes.

While the drugs are expensive and economic considerations are complex, the cost of not treating obesity at early stages, “thus enabling the progression to complications and end-organ damage, should be weighed equally in health policy and clinical decision-making,” the guideline authors wrote.

The management of obesity should not be limited to weight loss and its complications but should focus on enhanced mental well-being, physical fitness, social functioning, and overall health and quality of life as well, they also said.

Most of the newer medications have not been evaluated for the treatment of individual complications, they acknowledge.

Still, the authors say, the weight-loss effects have been strongly associated with improvements in various complications and there is growing potential for them to positively influence a broader range of disorders such as chronic kidney disease, neurodegenerative diseases, polycystic ovary syndrome, certain cancers, and mental health conditions.

“Given the rapid advances in the field of medications to treat obesity, EASO intends to update the present treatment algorithm regularly to incorporate the latest available evidence,” society President Professor Volkan Yumuk of Istanbul University-Cerrahpaşa said in a statement.

The American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society jointly advised in June that GLP-1 treatment must be accompanied by nutritional and lifestyle strategies.

“Although GLP‐1s alone can produce significant weight reduction and related health benefits, several challenges limit its long‐term success for individuals and populations,” including gastrointestinal side effects, risk of nutrient inadequacies, muscle and bone loss, high costs, frequent discontinuation, and weight regain,” the advisory said.

Reporting by Nancy Lapid; Editing by Caroline Humer, Bill Berkrot and Louise Heavens

Our Standards: The Thomson Reuters Trust Principles.opens new tab

What are the key mechanisms through which Wegovy (semaglutide) and Mounjaro/Zepbound (tirzepatide) contribute to weight loss?

European Doctors advocate Novo Nordisk and Eli Lilly Weight-Loss Drugs as Primary Obesity Treatment Options

The Shifting Paradigm in Obesity Management

European medical professionals are increasingly endorsing medications like Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Mounjaro (tirzepatide) – and now Zepbound (tirzepatide) – not merely as adjuncts to lifestyle interventions, but as primary treatment options for obesity. This represents a significant shift in how obesity, a chronic disease, is approached. For years, the focus remained heavily on diet and exercise, often with limited long-term success. Now, a growing body of clinical evidence supports the efficacy of these GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists in achieving significant and sustained weight loss.

This change isn’t about dismissing the importance of healthy habits; it’s about recognizing that obesity is a complex physiological condition often requiring pharmacological intervention. The conversation around weight management is evolving.

Understanding the Medications: Wegovy, Mounjaro & Zepbound

These drugs mimic naturally occurring hormones in the body, influencing appetite and food intake. Here’s a breakdown:

* Wegovy (Semaglutide): A GLP-1 receptor agonist originally approved for type 2 diabetes, Wegovy is now specifically indicated for chronic weight management.It works by slowing gastric emptying, increasing feelings of fullness, and reducing appetite. Clinical trials have demonstrated an average weight loss of around 15% in patients using Wegovy alongside lifestyle changes.

* Mounjaro/Zepbound (tirzepatide): A dual GIP and GLP-1 receptor agonist,tirzepatide has shown even more impressive results in clinical trials. Zepbound, the higher-dose version specifically for obesity, has demonstrated average weight loss exceeding 20% in clinical studies. It impacts both appetite and glucose regulation.

* Mechanism of Action: Both classes of drugs work on the brain’s appetite centers, reducing cravings and promoting satiety. They also improve insulin sensitivity, which is particularly beneficial for individuals with obesity and related metabolic disorders.

Why the Change in Approach? Evidence & Clinical Data

The advocacy from European doctors isn’t based on hype; it’s rooted in robust clinical data. Several factors contribute to this shift:

  1. High Obesity Rates: Europe, like much of the world, is facing an obesity epidemic. Customary methods haven’t adequately addressed the scale of the problem.
  2. Chronic Disease Recognition: Obesity is now widely recognized as a chronic, relapsing disease, not simply a matter of willpower. This understanding necessitates a more thorough and frequently enough pharmacological approach.
  3. Clinical Trial Results: Landmark trials, such as the SELECT trial with semaglutide demonstrating cardiovascular benefits in overweight/obese individuals without diabetes, have bolstered confidence in these medications.
  4. comorbidity reduction: these drugs have been shown to improve or resolve obesity-related comorbidities like type 2 diabetes, hypertension, sleep apnea, and non-alcoholic fatty liver disease (NAFLD). This holistic benefit is a key driver of physician support.

Benefits Beyond Weight Loss: A holistic Impact

The advantages of utilizing these medications extend far beyond the numbers on the scale.

* Improved Cardiovascular Health: Reduced risk of heart attack, stroke, and other cardiovascular events.

* Diabetes Management: Enhanced glycemic control and potential for diabetes remission.

* Reduced Joint Pain: Weight loss alleviates stress on joints, improving mobility and reducing pain.

* Enhanced Quality of Life: Improved physical function, mental well-being, and overall quality of life.

* Metabolic Syndrome Resolution: Advancement in multiple metabolic risk factors associated with metabolic syndrome.

Practical Considerations for Patients & Physicians

While these medications offer significant promise, they aren’t without considerations:

* Side Effects: Common side effects include nausea, vomiting, diarrhea, and constipation. These are typically mild to moderate and often subside with continued use.

* Cost & Access: The cost of these medications can be substantial, and access may be limited depending on healthcare systems and insurance coverage.

* Lifestyle Integration: These drugs are most effective when combined with lifestyle modifications,including a healthy diet and regular physical activity. They are not a “magic bullet.”

* Long-Term Use: Obesity is a chronic condition, and long-term medication use may be necessary to maintain weight loss.

* Monitoring: Regular monitoring by a healthcare professional is crucial to assess efficacy, manage side effects, and ensure overall health.

real-World Examples & emerging Trends

Several European countries are actively integrating these medications into their national obesity treatment guidelines. For exmaple, the UK’s National Health Service (NHS) has begun offering Wegovy to eligible patients through a structured weight management program. Denmark has also seen widespread adoption.

Furthermore,research is ongoing to explore the potential of combination therapies and personalized treatment approaches based on individual patient characteristics.The future of obesity treatment is highly likely to involve a more tailored and multifaceted approach,with medications playing a central role.

Addressing Concerns & Misconceptions

There’s been some public debate surrounding the use of these drugs, with concerns about potential rebound weight gain after discontinuation. While this is a valid concern, studies suggest that maintaining lifestyle changes after stopping medication can mitigate this risk. It’s crucial to have open and honest conversations with patients about

0 comments
0 FacebookTwitterPinterestEmail
world

Eli Lilly raises obesity medication by 170% in the UK | Reuters

by Omar El Sayed - World Editor
written by Omar El Sayed - World Editor

Eli Lilly’s Shocking Price Hike for Obesity Drug Manjaro in the UK: A Breaking News Update

London, UK – August 14, 2024 – In a move sparking immediate concern, pharmaceutical giant Eli Lilly (LLY.N) announced today a substantial price increase for its obesity treatment, Manjaro, in the United Kingdom. The price jump, reaching up to 170%, will significantly impact individuals paying out-of-pocket for the medication, raising questions about access and affordability. This is a developing story, and we’re bringing you the latest updates as they unfold – optimized for Google News and SEO visibility.

A box of Manjaro, Eli Lilly’s obesity treatment drug. (Reuters/George Frey, 2023)

The Price Surge: Details and Impact

Currently priced at £122 for the highest dose monthly supply, Manjaro will now cost £330 – a staggering 170% increase. This change, effective in September, also applies to the same drug when prescribed for Type 2 diabetes. While the National Health Service (NHS) patients will be shielded from this immediate impact, those self-funding their prescriptions face a considerable financial burden. This isn’t just about numbers; it’s about real people struggling with weight management and diabetes who now face a much steeper path to treatment.

Trump Administration’s Influence: A Global Pricing Strategy?

The timing of this price increase is particularly noteworthy. Eli Lilly cited a shift towards “more consistent” pricing with other European markets as the rationale. However, sources indicate a key driver is pressure from the Trump administration. The US government is actively encouraging pharmaceutical companies to maintain higher prices in Europe, with the aim of negotiating lower drug costs within the United States. This reveals a complex interplay between international trade, pharmaceutical pricing, and domestic political pressures. It’s a fascinating, and frankly concerning, example of how global healthcare economics are being reshaped.

Manjaro: Beyond Weight Loss – Understanding the Drug

Manjaro (tirzepatide) isn’t simply a weight-loss drug; it’s a dual-acting glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. This means it works on multiple pathways in the body to improve blood sugar control and promote weight loss. Originally approved for Type 2 diabetes, its efficacy in obesity has led to a surge in demand. The drug mimics natural hormones, helping individuals feel fuller for longer and reducing appetite. Its effectiveness has made it a highly sought-after treatment, but also a target for pricing scrutiny.

The UK Healthcare Landscape and NHS Considerations

The UK’s NHS operates on a different model than the US healthcare system. The NHS negotiates drug prices directly with pharmaceutical companies, ensuring affordability for patients. Eli Lilly initially priced Manjaro lower in the UK to facilitate access through the NHS, fearing supply disruptions if prices were too high. This initial strategy highlights the delicate balance between profitability and public health. The NHS’s bulk purchasing power is a crucial factor in keeping drug costs manageable for UK citizens.

Global Drug Pricing: A Growing Crisis

The United States consistently pays the highest prescription drug prices in the world, often nearly triple those of other developed nations. This disparity has fueled a long-standing debate about drug affordability and access. President Trump’s push to address this issue, while controversial, underscores the urgency of the situation. The current situation with Manjaro is a microcosm of a much larger problem: the unsustainable cost of prescription medications and the ethical implications of prioritizing profit over patient well-being. Understanding the nuances of pharmaceutical SEO and how news is indexed by Google is crucial for staying informed about these critical developments.

This price hike is a stark reminder of the complexities surrounding pharmaceutical pricing and the need for continued scrutiny and advocacy. Stay tuned to archyde.com for ongoing coverage of this developing story and in-depth analysis of the global healthcare landscape. We’ll continue to provide you with the latest breaking news and insightful commentary.


Eli Lilly Manjaro Price Hike

0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts
@2025 - All Right Reserved.

Hosted by ByoHosting - Most Recommendeed Webhhosting. For complains, abuse, advertising contact:
[email protected]

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.